tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Optimistic Buy Rating for enGene Holdings Amid LEGEND Study Progress and Regulatory Advancements
PremiumRatingsOptimistic Buy Rating for enGene Holdings Amid LEGEND Study Progress and Regulatory Advancements
3M ago
enGene price target lowered to $19 from $34 at Morgan Stanley
Premium
The Fly
enGene price target lowered to $19 from $34 at Morgan Stanley
3M ago
enGene Holdings Reports Q2 2025 Financial Results
Premium
Company Announcements
enGene Holdings Reports Q2 2025 Financial Results
3M ago
enGene appoints Amy Pott as chief global commercialization officer
PremiumThe FlyenGene appoints Amy Pott as chief global commercialization officer
3M ago
enGene reports inducement grants under NASDAQ listing rule
Premium
The Fly
enGene reports inducement grants under NASDAQ listing rule
5M ago
Promising Outlook for enGene Holdings: Buy Rating Justified by Strong Clinical Progress and Financial Resilience
Premium
Ratings
Promising Outlook for enGene Holdings: Buy Rating Justified by Strong Clinical Progress and Financial Resilience
6M ago
enGene initiated with an Overweight at Piper Sandler
PremiumThe FlyenGene initiated with an Overweight at Piper Sandler
7M ago
Buy Rating for enGene Holdings: Strategic Positioning and Growth Potential in NMIBC Market
Premium
Ratings
Buy Rating for enGene Holdings: Strategic Positioning and Growth Potential in NMIBC Market
7M ago
enGene downgraded to Neutral from Buy at UBS
Premium
The Fly
enGene downgraded to Neutral from Buy at UBS
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100